PMID: 12133923

Corbetta C, Seia M, Bassotti A, Ambrosioni A, Giunta A, Padoan R
Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
J Med Screen. 2002;9(2):60-3., [PubMed]
Sentences
No. Mutations Sentence Comment
266 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 12133923:266:241
status: NEW
view ABCC7 p.Gly551Asp details
ABCC7 p.Arg117His
X
ABCC7 p.Arg117His 12133923:266:61
status: NEW
view ABCC7 p.Arg117His details
ABCC7 p.Ala455Glu
X
ABCC7 p.Ala455Glu 12133923:266:123
status: NEW
view ABCC7 p.Ala455Glu details
ABCC7 p.Trp1282*
X
ABCC7 p.Trp1282* 12133923:266:333
status: NEW
view ABCC7 p.Trp1282* details
ABCC7 p.Arg553*
X
ABCC7 p.Arg553* 12133923:266:248
status: NEW
view ABCC7 p.Arg553* details
ABCC7 p.Arg334Trp
X
ABCC7 p.Arg334Trp 12133923:266:116
status: NEW
view ABCC7 p.Arg334Trp details
ABCC7 p.Arg347Pro
X
ABCC7 p.Arg347Pro 12133923:266:102
status: NEW
view ABCC7 p.Arg347Pro details
ABCC7 p.Arg347His
X
ABCC7 p.Arg347His 12133923:266:109
status: NEW
view ABCC7 p.Arg347His details
ABCC7 p.Asn1303Lys
X
ABCC7 p.Asn1303Lys 12133923:266:355
status: NEW
view ABCC7 p.Asn1303Lys details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 12133923:266:234
status: NEW
view ABCC7 p.Gly542* details
ABCC7 p.Arg1162*
X
ABCC7 p.Arg1162* 12133923:266:315
status: NEW
view ABCC7 p.Arg1162* details
ABCC7 p.Gln493*
X
ABCC7 p.Gln493* 12133923:266:202
status: NEW
view ABCC7 p.Gln493* details
ABCC7 p.Val520Phe
X
ABCC7 p.Val520Phe 12133923:266:209
status: NEW
view ABCC7 p.Val520Phe details
ABCC7 p.Ser549Arg
X
ABCC7 p.Ser549Arg 12133923:266:262
status: NEW
view ABCC7 p.Ser549Arg details
ABCC7 p.Gly85Glu
X
ABCC7 p.Gly85Glu 12133923:266:38
status: NEW
view ABCC7 p.Gly85Glu details
ABCC7 p.Ser549Asn
X
ABCC7 p.Ser549Asn 12133923:266:269
status: NEW
view ABCC7 p.Ser549Asn details
ABCC7 p.Tyr122*
X
ABCC7 p.Tyr122* 12133923:266:68
status: NEW
view ABCC7 p.Tyr122* details
ABCC7 p.Arg560Thr
X
ABCC7 p.Arg560Thr 12133923:266:255
status: NEW
view ABCC7 p.Arg560Thr details
Mutations identified by the assay are G85E, 621+1G→T, R117H, Y122X, 711+1G→T, 1078delT, R347P, R347H, R334W, A455E, 1898+1G→A, 2183-AA→G, 2789+5G→A, delF508, I507del, Q493X, V520F, 1717-1G→A, G542X, G551D, R553X, R560T, S549R, S549N, 3849+10kbC→T, 3849+4A→G, R1162X, 3659delC, W1282X, 3905insT, and N1303K. Login to comment
280 ABCC7 p.Arg334Trp
X
ABCC7 p.Arg334Trp 12133923:280:166
status: NEW
view ABCC7 p.Arg334Trp details
ABCC7 p.Asn1303Lys
X
ABCC7 p.Asn1303Lys 12133923:280:123
status: NEW
view ABCC7 p.Asn1303Lys details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 12133923:280:173
status: NEW
view ABCC7 p.Gly542* details
Genotypes are shown in table 1: 18% of our patients were delF508 homozygotes, 15% were homozygotes for other CFTR alleles (N1303K, 2183AA→G, 1717-1G→A, R334W, G542X), 21% were compound heterozygotes, and a further 43% were heterozygotes. Login to comment
285 ABCC7 p.Arg117His
X
ABCC7 p.Arg117His 12133923:285:137
status: NEW
view ABCC7 p.Arg117His details
ABCC7 p.Trp1282*
X
ABCC7 p.Trp1282* 12133923:285:262
status: NEW
view ABCC7 p.Trp1282* details
ABCC7 p.Arg347His
X
ABCC7 p.Arg347His 12133923:285:170
status: NEW
view ABCC7 p.Arg347His details
ABCC7 p.Asn1303Lys
X
ABCC7 p.Asn1303Lys 12133923:285:117
status: NEW
view ABCC7 p.Asn1303Lys details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 12133923:285:152
status: NEW
view ABCC7 p.Gly542* details
ABCC7 p.Arg1162*
X
ABCC7 p.Arg1162* 12133923:285:177
status: NEW
view ABCC7 p.Arg1162* details
The CFTR mutations identified and their frequencies among carriers were as follows: delF508 (72 chromosomes, 64.2%), N1303K (12, 10.7%), R117H (9, 8%), G542X (7, 6.25%), R347H, R1162X, 2789+5G→A (2 alleles each, 1.8%), 1898+1G→A, 1717-1G→A, W1282X, 2183-AA→G, 621+1G→T, and 3849+10kbC→T (1, 0.9%). Login to comment
286 ABCC7 p.Arg117His
X
ABCC7 p.Arg117His 12133923:286:43
status: NEW
view ABCC7 p.Arg117His details
In this group we found a greater number of R117H carriers than expected. Login to comment
301 ABCC7 p.Gly85Glu
X
ABCC7 p.Gly85Glu 12133923:301:310
status: NEW
view ABCC7 p.Gly85Glu details
We think that the difference in prevalence over the two periods has been because of the greater chance of recognising subjects with only one identified CFTR mutation, who can then be forwarded for a sweat test, owing to the wider DNA strategy (one case with a recall IRT under the cut off value had a genotype G85E/unknown), and because of the new definition of the upper normal value for the chloride sweat test in our laboratory (30 mmol/l). Login to comment
302 ABCC7 p.Asp1152His
X
ABCC7 p.Asp1152His 12133923:302:161
status: NEW
view ABCC7 p.Asp1152His details
ABCC7 p.Asp579Gly
X
ABCC7 p.Asp579Gly 12133923:302:192
status: NEW
view ABCC7 p.Asp579Gly details
ABCC7 p.Asp110Asn
X
ABCC7 p.Asp110Asn 12133923:302:177
status: NEW
view ABCC7 p.Asp110Asn details
The last led to a CF diagnosis in infants with sweat chloride values between 30 and 60 mmol/l, who underwent gene scanning (three infants with genotypes delF508/D1152H, delF508/D110N, delF508/D579G). Login to comment
306 ABCC7 p.Asp110Glu
X
ABCC7 p.Asp110Glu 12133923:306:138
status: NEW
view ABCC7 p.Asp110Glu details
The first had only one CFTR mutated allele (711+3A→G), the second, a girl of Tunisian origin, was homozygous for a novel mutation (D110E).22 The observed carrier frequency was 1:13 hypertrypsinaemic newborn infants, whereas in the previous period 1:24 hypertrypsinaemic infants were detected as delF508 carriers. Login to comment
310 ABCC7 p.Trp1282*
X
ABCC7 p.Trp1282* 12133923:310:646
status: NEW
view ABCC7 p.Trp1282* details
ABCC7 p.Arg334Trp
X
ABCC7 p.Arg334Trp 12133923:310:351
status: NEW
view ABCC7 p.Arg334Trp details
ABCC7 p.Arg334Trp
X
ABCC7 p.Arg334Trp 12133923:310:357
status: NEW
view ABCC7 p.Arg334Trp details
ABCC7 p.Asn1303Lys
X
ABCC7 p.Asn1303Lys 12133923:310:313
status: NEW
view ABCC7 p.Asn1303Lys details
ABCC7 p.Asn1303Lys
X
ABCC7 p.Asn1303Lys 12133923:310:320
status: NEW
view ABCC7 p.Asn1303Lys details
ABCC7 p.Asn1303Lys
X
ABCC7 p.Asn1303Lys 12133923:310:342
status: NEW
view ABCC7 p.Asn1303Lys details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 12133923:310:378
status: NEW
view ABCC7 p.Gly542* details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 12133923:310:386
status: NEW
view ABCC7 p.Gly542* details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 12133923:310:392
status: NEW
view ABCC7 p.Gly542* details
ABCC7 p.Arg1162*
X
ABCC7 p.Arg1162* 12133923:310:472
status: NEW
view ABCC7 p.Arg1162* details
ABCC7 p.Gly85Glu
X
ABCC7 p.Gly85Glu 12133923:310:685
status: NEW
view ABCC7 p.Gly85Glu details
Since 1998, in our CF centre, an expanded DNA CFTR gene analysis and repeat sweat test after 6-12 months of life have been performed in hypertrypsinaemic Table 1 Genotypes of 33 patients with CF identified in the 15 month period Two CFTR mutations identified (18 patients) by PCR/OLA: ∆F508/∆F508 6 N1303K/N1303K 2 ∆F508/N1303K 3 R334W/R334W 1 ∆F508/G542X 2 G542X/G542X 1 ∆F508/3659delC 1 2183AA→G/ 2183AA→G 1 ∆F508/R1162X 1 One CFTR mutation identified (13 patients) by PCR/OLA: ∆F508/D1152H* 1 ∆F508/Y1032C* 1 ∆F508/R1066H* 1 ∆F508/UN 6 ∆F508/R1066C* 1 W1282X/L1077P* 1 ∆F508/D579G* 1 G85E/UN 1 No CFTR mutation identified (two patients) by PCR/OLA: 711+3A→G*/UN 1 D110E*/D110E* 1 *CFTR alleles identified by analysis by denaturing gradient gel electrophoresis and sequencing. Login to comment
312 ABCC7 p.Arg117His
X
ABCC7 p.Arg117His 12133923:312:205
status: NEW
view ABCC7 p.Arg117His details
These patients are then followed up at the CF centre, and receive a global approach to exclude or confirm CF diagnosis and correct genetic counselling.25 An unexpectedly high frequency of carriers for the R117H allele was found: we think that several people with this allele plus a second CFTR mutation leading to very mild disease or to a borderline or negative sweat test in the first months of life26 may still be undetected. Login to comment